Literature DB >> 17852789

Hypercoagulability and platelet inhibition after OPCAB. Randomized intervention with clopidogrel.

Allan Bybeck Nielsen1, Louise Bochsen, Daniel A Steinbrüchel.   

Abstract

OBJECTIVE: Data on graft patency after Off-Pump Coronary Artery Bypass (OPCAB) suggest that the incidence of early graft closure is not increased compared to conventional coronary artery bypass surgery. However, hypercoagulability following OPCAB is still of concern, and acetylsalicylic acid as thromboembolic prophylaxis might be insufficient in the first weeks following OPCAB surgery.
DESIGN: Twenty nine patients were randomly assigned to+/- 75 mg of clopidogrel until 30 days after OPCAB surgery. The follow-up time was 2 months including standard blood samples and thrombelastography (TEG) with a specific platelet inhibition assay, which was evaluated as a part of the study.
RESULTS: In both groups a significant increase in TEG maximum amplitude was found 5 days after surgery. Platelet inhibition showed great variations but was significantly increased in the clopidogrel group (34.1%) vs. control group (11.0%) after 1 month.
CONCLUSION: Hypercoagulability was seen 5 days after OPCAB and could not be demonstrated after 1 month. No clinical effects of the hypercoagulability were observed, and further research is needed to determine if clopidogrel should be recommended after OPCAB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852789     DOI: 10.1080/14017430701383763

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  1 in total

Review 1.  Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials.

Authors:  Subodh Verma; Shaun G Goodman; Shamir R Mehta; David A Latter; Marc Ruel; Milan Gupta; Bobby Yanagawa; Mohammed Al-Omran; Nandini Gupta; Hwee Teoh; Jan O Friedrich
Journal:  BMC Surg       Date:  2015-10-14       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.